StonvexLoading…
StonvexStonvexStonvexCore line items from AORT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $441.33M | $388.54M | $354.00M | $313.79M |
Operating Income | $33.74M | $38.87M | $5.74M | $6.20M |
Net Income | $9.77M | $-13.36M | $-30.69M | $-19.19M |
EPS (Diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 |
Total Assets | $884.80M | $789.10M | $792.40M | $762.80M |
Total Liabilities | $436.56M | $512.90M | $510.62M | $478.47M |
Cash & Equivalents | $64.91M | $53.46M | $58.94M | $39.35M |
Free Cash Flow OCF − CapEx | $839.00K | $11.05M | $9.07M | $-15.87M |
Shares Outstanding | 47.16M | 41.68M | 40.74M | 40.03M |